Search

Scientists are learning how tumors develop resistance to drugs — and what can be done about it.

Meet Victoria “Vikki” Mills, Associate Director of Research Administration Operations at Memorial Sloan Kettering, who is deeply satisfied with her work and delighted with her family, which will soon expand — Vikki is expecting her second child in August with her fiancée, Shauna.

Scientists at Sloan Kettering Institute have discovered that the α6ß4 integrin, one of several receptor proteins, plays a key role in signaling for the formation of new blood vessels for a tumor, a process called tumor angiogenesis. By blocking the signaling activity of the α6ß4 subunit of this integrin on vascular cells, researchers found they could slow the growth of tumors.

MSK surgeon James Eastham explains the pros and cons of PSA testing and weighs in on a new US Preventive Services Task Force guideline.

Researchers have gained new understanding of how tumors metastasize by studying the behavior of exceptional breast and lung cancer cells that are capable of entering the brain and surviving there.

Combining checkpoint blockade with engineered T cells may lead to longer-lasting results in patients with breast cancer, lung cancer, and other solid tumors.

Cancers linked to HPV are on the rise. But only a little over half of all adolescents in the U.S. got the full series of vaccinations. In this Q&A, Chrisann Kyi talks about why it's so important for young people to get vaccinated.

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute explores ways to limit heart damage from chemotherapy and radiation; examines genomic differences between primary and metastatic tumors in bladder cancer; aims to understand the safety of check point inhibitor therapy for patients who are obese; and investigates a potential therapeutic approach against acute myeloid leukemia.